1	Integrated host-microbe metagenomics for sepsis diagnosis in critically ill adults
2	
3	*Katrina Kalantar ¹ , *Lucile Neyton ² , Mazin Abdelghany ³ , Eran Mick ³ , Alejandra Jauregui ² ,
4	Saharai Caldera ³ , Paula Hayakawa Serpa ³ , Rajani Ghale ^{2,3} , Jack Albright ⁴ , Aartik Sarma ² ,
5	Alexandra Tsitsiklis ³ , Aleksandra Leligdowicz ⁴ , Stephanie Christenson ² , Kathleen Liu ⁵ , Kirsten
6	Kangelaris ⁶ , Carolyn Hendrickson ³ , Pratik Sinha ⁷ , Antonio Gomez ⁸ , Norma Neff ⁹ , Angela Pisco ⁹ ,
7	Sarah Doernberg ³ , Joseph L. Derisi ^{9,10} , Michael A. Matthay ² , [†] Carolyn S. Calfee ² , [†] Charles R.
8	Langelier ^{3,9} .
9	* [†] equal contributions
10	
11	
12	Affiliations:
13	¹ Chan Zuckerberg Initiative, San Francisco, CA, USA
14	² Department of Medicine, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine,
15	University of California San Francisco, San Francisco, CA, USA
16	³ Department of Medicine, Division of Infectious Diseases, University of California San
17	Francisco, San Francisco, CA, USA
18	⁴ Department of Critical Care Medicine, Western University, London, Ontario, Canada
19	⁵ Department of Medicine, Division of Nephrology, University of California San Francisco, San
20	Francisco, CA, USA
21	⁶ Department of Medicine, University of California San Francisco, San Francisco, CA, USA
22	⁷ Washington University, St Louis, St. Louis, MO, USA
23	⁸ Department of Medicine, Zuckerberg San Francisco General Hospital, San Francisco, CA, USA
24	⁹ Chan Zuckerberg Biohub, San Francisco, CA, USA

- ¹⁰Department of Biochemistry and Biophysics, University of California San Francisco, San
- 26 Francisco, CA, USA
- 27
- 28 **Keywords:** sepsis, metagenomics, transcriptional profiling, classifier, machine learning, plasma

29 Abstract

30 Sepsis is a leading cause of death, and improved approaches for disease diagnosis and 31 detection of etiologic pathogens are urgently needed. Here, we carried out integrated host and 32 pathogen metagenomic next generation sequencing (mNGS) of whole blood (n=221) and 33 plasma RNA and DNA (n=138) from critically ill patients following hospital admission. We 34 assigned patients into sepsis groups based on clinical and microbiological criteria: 1) sepsis with bloodstream infection (Sepsis^{BSI}), 2) sepsis with peripheral site infection but not bloodstream 35 36 infection (Sepsis^{non-BSI}). 3) suspected sepsis with negative clinical microbiological testing: 4) no 37 evidence of infection (No-Sepsis), and 5) indeterminant sepsis status. From whole blood gene 38 expression data, we first trained a bagged support vector machine (bSVM) classifier to 39 distinguish Sepsis^{BSI} and Sepsis^{non-BSI} patients from No-Sepsis patients, using 75% of the cohort. 40 This classifier performed with an area under the receiver operating characteristic curve (AUC) of 41 0.81 in the training set (75% of cohort) and an AUC of 0.82 in a held-out validation set (25% of 42 cohort). Surprisingly, we found that plasma RNA also yielded a biologically relevant 43 transcriptional signature of sepsis which included several genes previously reported as sepsis 44 biomarkers (e.g., HLA-DRA, CD-177). A bSVM classifier for sepsis diagnosis trained on RNA gene expression data performed with an AUC of 0.97 in the training set and an AUC of 0.77 in a 45 46 held-out validation set. We subsequently assessed the pathogen-detection performance of DNA 47 and RNA mNGS by comparing against a practical reference standard of clinical bacterial culture 48 and respiratory viral PCR. We found that sensitivity varied based on site of infection and 49 pathogen, with an overall sensitivity of 83%, and a per-pathogen sensitivity of 100% for several 50 key sepsis pathogens including S. aureus, E. coli, K. pneumoniae and P. aeruginosa. 51 Pathogenic bacteria were also identified in 10/37 (27%) of patients in the No-Sepsis group. To 52 improve detection of sepsis due to viral infections, we developed a secondary RNA host 53 transcriptomic classifier which performed with an AUC of 0.94 in the training set and an AUC of 54 0.96 in the validation set. Finally, we combined host and microbial features to develop a proof-

- 55 of-concept integrated sepsis diagnostic model that identified 72/73 (99%) of microbiologically
- 56 confirmed sepsis cases, and predicted sepsis in 14/19 (74%) of suspected, and 8/9 (89%) of
- 57 indeterminate sepsis cases. In summary, our findings suggest that integrating host
- 58 transcriptional profiling and broad-range metagenomic pathogen detection from nucleic acid
- 59 may hold promise as a tool for sepsis diagnosis.

60 Introduction

Sepsis causes 20% of all deaths globally and contributes to 20-50% of hospital deaths in the United States alone^{1,2}. Early diagnosis and identification of the underlying microbial pathogens is essential for timely and appropriate antibiotic therapy, which is critical for sepsis survival^{3,4}. Yet in over 30% of cases, no etiologic pathogen is identified⁵, reflecting the limitations of current culture-based microbiologic diagnostics⁶. Adding additional complexity is the need to differentiate sepsis effectively from non-infectious systemic illnesses, which often appear clinically similar at the time of hospital admission.

68 As a result, antibiotic treatment often remains empiric rather than pathogen-targeted, 69 with clinical decision-making based on epidemiological information rather than individual patient 70 data. Similarly, clinicians often continue empiric antimicrobials despite negative microbiologic 71 testing for fear of harming patients in the setting of falsely negative results. Both scenarios lead 72 to antimicrobial overuse and misuse, which contributes to treatment failures, opportunistic 73 infections such as C. difficile colitis, and the emergence of drug-resistant organisms⁷. 74 With the introduction of culture-independent methods such as metagenomic next generation sequencing (mNGS), limitations in sepsis diagnostics may be overcome^{8,9}. Recent 75 76 advancements in plasma cell-free DNA sequencing have expanded the scope of metagenomic 77 diagnostics by enabling minimally invasive detection of circulating pathogen nucleic acid 78 originating from diverse anatomical sites of infection⁹. The clinical impact of plasma DNA 79 metagenomics has been questioned, however, due to frequent identification of microbes of 80 uncertain clinical significance, inability to detect RNA viruses that cause pneumonia, and limited utility in ruling-out presence of infection^{10,11}. 81

Whole blood transcriptional profiling offers the potential to mitigate these limitations by capturing host gene expression signatures that distinguish infectious from non-infectious conditions, and viral from bacterial infections^{12,13}. However, because transcriptional profiling exclusively captures the host response to infection, it does not provide precise taxonomic

identification of sepsis pathogens, which limits the utility of this approach when performed alone.
Further, transcriptional profiling has traditionally required isolating peripheral-blood mononuclear
cells, or stabilizing whole blood in specialized collection tubes, and it has remained unknown
whether a simple plasma specimen could yield informative data for host-based infectious
disease diagnosis.

91 In recent work, a single-sample metagenomic approach combining host transcriptional 92 profiling with unbiased pathogen detection was developed to improve lower respiratory tract 93 infection diagnosis¹⁴. Sepsis, defined as, "life-threatening organ dysfunction from a dysregulated 94 host response to infection¹⁵," provides an additional clear use case for this integrated host-95 microbe metagenomics approach. Here, we study a prospective cohort of critically ill adults to 96 develop a novel sepsis diagnostic assay that combines host transcriptional profiling with broad-97 range pathogen identification. By applying machine learning to high dimensional mNGS data, 98 we evaluate host and microbial features that distinguish microbiologically confirmed sepsis from 99 non-infectious critical illness. We then demonstrate that plasma nucleic acid can be used to 100 profile both host and microbe for precision sepsis diagnosis.

101

102 Results

103 Clinical features of study cohort

104 We conducted a prospective observational study of critically ill adults admitted from the 105 Emergency Department (ED) to the Intensive Care Unit (ICU) at two tertiary care hospitals 106 (Figure 1). Patients were categorized into five subgroups based on sepsis status (Methods). 107 These included patients with: 1) clinically adjudicated sepsis and a microbiologically confirmed 108 bacterial bloodstream infection (Sepsis^{BSI}), 2) clinically adjudicated sepsis and a 109 microbiologically confirmed non-bloodstream infection (Sepsis^{non-BSI}), 3) suspected sepsis with negative clinical microbiologic testing (Sepsis^{suspected}), 4) patients with no evidence of sepsis and 110 111 a clear alternative explanation for their critical illness (No-Sepsis), or 5) patients of indeterminant

112 status (Indeterm). The most common diagnoses in the No-Sepsis group were cardiac arrest,

- 113 overdose/poisoning, heart failure exacerbation, and pulmonary embolism. The majority of
- 114 patients, regardless of subgroup, required mechanical ventilation and vasopressor support
- 115 (Supplementary Table 1). Patients with microbiologically proven sepsis (Sepsis^{BSI} + Sepsis^{non-}
- ^{BSI}) did not differ from No-Sepsis patients in terms of age, gender, race, ethnicity,
- 117 immunocompromise, APACHEIII score, maximum white blood cell count, intubation status, or
- 118 28-day mortality (Figure 1, Supplementary Table 1). All but one patient (in the No-Sepsis
- 119 group) exhibited \geq 2 systemic inflammatory response syndrome (SIRS) criteria¹⁶.

120 Host transcriptional signature of sepsis from whole blood

121 We first assessed transcriptional differences between patients with clinically and

122 microbiologically confirmed sepsis (Sepsis^{BSI}, Sepsis^{non-BSI}) versus those without evidence of

123 infection (No-Sepsis) by performing RNA sequencing (RNA-seq) on whole blood specimens (n

124 = 221 total) to obtain a median of 5.8×10^7 (95% CI 5.3-6.3 x 10⁷) reads per sample. 5,807

125 differentially expressed (DE) genes were identified at an adjusted P value < 0.1 (Figure 2a,

126 **Supplementary Data 1**). Gene set enrichment analysis (GSEA), a method that identifies groups

127 of genes within a dataset sharing common biological functions¹⁷, demonstrated upregulation of

128 genes related to neutrophil degranulation and innate immune signaling in the patients with

129 sepsis, with concomitant downregulation of pathways related to translation and rRNA

130 processing (Figure 2b, Supplementary Data 2).

To further characterize differences between sepsis patients with bloodstream versus peripheral site (e.g., respiratory, urinary tract) infections, we performed differential gene expression (DE) analysis between the Sepsis^{BSI} and Sepsis^{non-BSI} groups, which identified 5,227 genes (**Supplementary Data 3**). GSEA demonstrated enrichment in genes related to CD28 signaling, immunoregulatory interactions between lymphoid and non-lymphoid cells, and other functions in the Sepsis^{non-BSI} patients, while the Sepsis^{BSI} group was characterized by

Given the practical necessity to identify sepsis in both Sepsis^{BSI} and Sepsis^{non-BSI}

137 enrichment in genes related to antimicrobial peptides, defensins, G alpha signaling and other

138 pathways (**Supplementary Data 4**).

140

139 Host transcriptional classifier for sepsis diagnosis from whole blood

141 patients, we constructed a 'universal' sepsis diagnostic classifier based on whole blood gene 142 expression signatures. After dividing the cohort (n=221) into independent training (75% of data, 143 n=165) and validation (25% of data, n=56) groups, we employed a bagged support vector 144 machine learning approach (bSVM) to select genes that most effectively distinguished patients 145 with sepsis (Sepsis^{BSI} and Sepsis^{non-BSI}) from those without (No-Sepsis). We elected to use a 146 bSVM model due to better performance compared to random forest and gradient boosted trees. 147 which were also tested (Supplementary Table 2). The bSVM model achieved an average 148 cross-validation AUC of 0.81 (standard deviation (SD) 0.05) over 10 random splits within the 149 training dataset (75% of data, n=165). In the held-out validation set (25% of data, n=56), an 150 AUC of 0.82 was obtained. Additionally, an AUC of 0.85 (SD 0.02) was obtained over 10 151 randomly-generated validation sets (Figure 2c, Supplementary Data 5). 152 Host transcriptional classifier for sepsis diagnosis from plasma RNA 153 Sequencing of plasma DNA has emerged as a preferred strategy for culture-154 independent detection of bacterial pathogens in the bloodstream⁹. It remained unknown, 155 however, whether plasma RNA could provide meaningful and biologically relevant gene 156 expression data, as sepsis transcriptional profiling studies have historically relied on isolation of

157 PBMCs or collection of whole blood.

To test this, we sequenced RNA from patients with available plasma specimens matched to the whole blood samples, and obtained a median of 2.3×10^7 (95% Cl 2.2-2.5 x 10⁷) reads per sample. Calculation of input RNA mass (**Methods**) demonstrated that samples with transcript counts below our QC cutoff (< 50,000) had a lower average input mass than those

162 with sufficient counts (65.2 pg versus 85.8 pg, respectively, p <0.0001, Supplementary Data 163 **8**). After filtering to retain samples with \geq 50,000 transcripts (n=138), we performed DE 164 analysis to assess whether a biologically plausible signal could be observed between patients 165 with sepsis (Sepsis^{BSI} and Sepsis^{non-BSI}, n=73) and those without (No-Sepsis, n=37), and found 166 62 genes at an adjusted P value < 0.1 (Supplementary Data 6), 28 of which were also 167 significant in the whole blood analysis (Supplementary Figure 1). Remarkably, several of the 168 top differentially expressed genes were previously reported sepsis biomarkers (e.g., elevated *CD177*, suppressed *HLA-DRA*),^{18–21} suggesting a biologically relevant transcriptomic signature 169 170 from plasma RNA (Figure 2d, Supplementary Data 6). 171 We then asked whether a host transcriptional sepsis diagnostic classifier could be

172 constructed using plasma RNA transcriptomic data by dividing the cohort into independent

training (75% of data, n=82) and validation groups (n=28), and employing the same bSVM

approach to select genes that most effectively distinguished Sepsis^{BSI} and Sepsis^{non-BSI} patients

175 from No-Sepsis patients. This approach yielded a classifier that achieved an average cross-

176 validation AUC of 0.97 (SD 0.03) over 10 random splits within the training dataset (75% of data,

177 n=82). In the held-out validation set (25% of data, n=28), an AUC of 0.77 was obtained. An AUC

178 of 0.90 (SD 0.06) was obtained over 10 randomly-generated validation sets (Figure 2e,

179 **Supplementary Data 7**).

180 Detection of bacterial sepsis pathogens from plasma nucleic acid

We began microbial metagenomic analyses by assessing DNA microbial mass (Methods), which was significantly lower in negative control water samples, but did not differ between adjudicated sepsis groups (Figure 3a, Supplementary Data 8). We next carried out bacterial pathogen detection using the IDseq pipeline²² for taxonomic alignment followed by a previously developed rules-based model (RBM)¹⁴ that identifies established sepsis pathogens overrepresented in mNGS data compared to less abundant commensal or contaminating

187 microbes¹⁴ (Methods, Figure 3b).

188	We then asked how well the metagenomic RBM pathogen predictions agreed with
189	bacterial blood culture data. Polymicrobial blood cultures of \geq 3 organisms were excluded (n=2)
190	given their unclear clinical significance, leaving a total of 40 blood culture-positive cases
191	available for comparison (Supplementary Data 9). Sensitivity versus blood culture as a
192	reference standard was 83%, and varied by pathogen, ranging from 0% (e.g., C. difficile) to
193	100% (e.g., E. coli, S. aureus/argenteus Figure 3c). Pathogens were called by the RBM in
194	10/37 (27%) of patients in the No-Sepsis group, equating to a specificity of 73%.
195	Detection of sepsis pathogens from peripheral sites using plasma nucleic acid
196	Plasma DNA mNGS identified 2/25 (8%) of culture-confirmed bacterial lower respiratory
197	tract infection (LRTI) pathogens in the Sepsis ^{non-BSI} group and 3/8 (38%) culture-confirmed
198	bacterial urinary tract infection (UTI) pathogens (Figure 3d, Supplementary Data 9). mNGS
199	did not identify C. difficile in any of the three patients with severe colitis from this organism.
200	Additional putative bacterial pathogens not detected by culture were detected in 8/73 (11%) of
201	patients with microbiologically confirmed sepsis (Supplementary Data 9).
202	Identification of viral infections using host transcriptional profiling of RNA and whole blood
203	Only one of 13 (8%) respiratory viruses identified by clinical testing could be detected by
204	plasma RNA mNGS (Supplementary Data 9). Recognizing that an alternative approach would
205	be needed, we asked whether host response could instead be used to identify viral sepsis by
206	carrying out differential gene expression analysis of patients with or without clinically confirmed
207	viral sepsis within the Sepsis ^{BSI} and Sepsis ^{non-BSI} groups, using whole blood (Supplementary
208	Data 10) or plasma (Supplementary Data 11) transcriptomic data. GSEA demonstrated that
209	pathways related to interferon signaling and genes important for antiviral immunity were
210	enriched in samples from patients with viral sepsis versus those with bacterial sepsis, in data
211	derived from both whole blood (Figure 4a, Supplementary Data 12a) and plasma (Figure 4b,

212 **Supplementary Data 12b**) datasets.

213 We then leveraged this host signature to build a secondary bSVM diagnostic classifier 214 for viral sepsis selecting differentially expressed genes as potential predictors, which on whole 215 blood samples achieved an average cross-validation AUC of 0.90 (SD 0.07) over 10 random 216 splits within the training dataset (75% of data, n=96). In the held-out validation set (25% of data, 217 n=33), an AUC of 0.79 was obtained. An AUC of 0.87 (SD 0.04) was obtained over 10 218 randomly-generated validation sets (Figure 4c, Supplementary Data 13). Slightly better 219 performance was obtained when building a classifier using plasma RNA-seg data, with an 220 average cross-validation AUC of 0.94 (SD 0.09) over 10 random splits within the training 221 dataset (75% of data, n=54). In the held-out validation set (25% of data, n=19), an AUC of 0.96 222 was obtained. An AUC of 0.94 (SD 0.07) was obtained over 10 randomly-generated validation 223 sets (Figure 4d, Supplementary Data 14). Incorporation of the host-based viral sepsis 224 classifier improved the sensitivity versus clinical respiratory viral PCR testing to 12/13 (92%). 225 and predicted viral infection in one additional Sepsis^{non-BSI} patient who didn't undergo viral PCR 226 testing (Supplementary Data 15).

227 Integrated host-microbe sepsis diagnostic model using plasma nucleic acid

228 Given the relative success of each independent host and pathogen model, we 229 considered whether combining them could enhance diagnosis, and potentially serve as a sepsis 230 rule-out tool. To test this possibility, we developed a proof-of-concept integrated host + microbe 231 model based on simple rules. It returned a sepsis diagnosis based on either host criteria: [host 232 sepsis classifier probability > 0.5] or microbial criteria: [(pathogen detected by RBM) 233 AND (microbial mass > 20 pg)] OR [host viral classifier probability > 0.9]. Applying 234 these rules enabled detection of 42/42 (100%) of cases in the Sepsis^{BSI} group and 30/31 (97%) 235 of cases in the Sepsis^{non-BSI} subjects, for an overall sensitivity of 72/73 (99%) (Figures 5a, 5b). 236 This proof-of-concept model yielded a specificity of 29/37 (78%) within the No-Sepsis subjects

237 (Figure 5c, Supplementary Data 15).

238 Application of the integrated model to suspected and indeterminant sepsis cases

239	Next, we asked whether patients with clinically adjudicated sepsis, but negative in-
240	hospital microbiologic testing (Sepsis ^{suspected}) would be predicted to have sepsis using the
241	integrated host-microbe plasma mNGS model. 14/19 (74%) were classified as having sepsis,
242	(Figure 5d), eight of which had a putative bacterial pathogen identified. Two additional patients
243	had viral host classifier probabilities > 0.5, but did not meet the threshold for sepsis-positivity in
244	the integrated model. With respect to the indeterminate group, the integrated host + microbe
245	model classified 8/9 (89%) as sepsis-positive (Figure 5e, Supplementary Data 15). Of these,
246	two had a putative bacterial pathogen identified and one had a putative viral infection identified
247	by the viral host classifier.
248	
249	Comparison against clinical variable models for sepsis diagnosis
250	Lastly, we asked how host/microbe mNGS compared against sepsis diagnostic models
251	derived exclusively from clinical metrics that would be available at the time of initial evaluation in
252	the ED. We tested three different machine learning methods to distinguish Sepsis (Sepsis ^{BSI}
253	and Sepsis ^{non-BSI}) from No-Sepsis patients, using 34 clinical variables as input (Supplementary
254	Table 3a). The data were split into training (75%) and validation (25%) sets, and model
255	performance was evaluated on the latter. The greatest average AUC achieved was 0.62 (SD
256	0.04) using a random forest model (Supplementary Table 3b). We then computed the AUC
257	using the qSOFA score, a widely used clinical score for sepsis diagnosis ¹⁵ . The qSOFA
258	achieved an average AUC of 0.48 (SD 0.02).
259	
260	Discussion

261 Sepsis is defined as a dysregulated host response to infection¹⁵, yet existing diagnostics

have focused exclusively on either detecting pathogens or assessing features of the infected
host. Here, we combined host transcriptional profiling with broad-range pathogen detection to
accurately diagnose sepsis in critically ill patients upon hospital admission. Further, we
demonstrate that an integrated host-microbe metagenomics approach can be performed on
circulating RNA and DNA from plasma, a widely available clinical specimen type with previously
unrecognized utility for host-based infectious disease diagnosis.

268 Identifying an etiologic pathogen is critical for optimal treatment of sepsis. We found that 269 concordance between pathogen detection by plasma mNGS and traditional bacterial blood 270 culture varied by organism. For instance, mNGS sensitivity for detecting S. aureus and E. coli, two of the most globally important sepsis pathogens⁵, was 100%. In contrast, mNGS missed 271 272 several important but less common sepsis pathogens, such as S. pyogenes. We noted that in all 273 false-negative cases, the patients had received antibiotics prior to mNGS sample collection, 274 which may have reduced the abundance of circulating bacterial DNA available for detection. 275 Furthermore, mNGS and blood cultures were performed on different samples, with research 276 specimens collected up to 24 hours after blood cultures, which may have resulted in lower 277 concordance than if samples had been collected contemporaneously.

278 Several of the microbes missed by mNGS were organisms that in many contexts exist 279 as commensals (e.g., Fusobacterium, Gemella and Streptococcus species). It is unclear 280 whether these organisms were truly etiologic sepsis pathogens or commensals translocated to 281 the blood in the setting of critical illness, and incidentally identified in culture. Clostridium 282 species are frequently found as contaminants in blood cultures²³, which is perhaps why mNGS 283 also did not detect an unspeciated Clostridium isolated in blood culture from one patient.

With respect to non-BSI sepsis, our findings suggest that plasma mNGS may be most useful for identifying UTI-associated pathogens, although we also observed some utility for respiratory pathogen detection, in line with a prior report²⁴. mNGS failed to detect *C. difficile* in any patients with colitis from this pathogen, although this is not surprising given that the

288 organism is rarely associated with bacteremia²⁵.

Within the No-Sepsis group, 10/37 (27%) of patients had a pathogen detected by mNGS, each of which was validated to be present at statistically significantly higher levels than in background controls. Notably, 9/10 (90%) of the pathogens were gram negative enteric organisms, which may reflect gastrointestinal translocation of microbes, a well described phenomenon during critical illness²⁶. In addition, all 10 of these patients had received antibiotics in the first day of study enrollment, so it is possible that sequences derived from non-viable organisms unable to grow in culture.

296 Plasma RNA sequencing alone performed poorly for detecting sepsis-associated 297 respiratory viruses. Incorporation of a host-based viral classifier, however, markedly improved 298 detection of clinically confirmed viral LRTI. The viral classifier predicted previously unrecognized 299 viral infections in three patients with sepsis who did not undergo viral PCR testing during their 300 hospitalizations. Prior work has demonstrated that different viral species elicit distinct host 301 transcriptional signatures in the peripheral blood²⁷, suggesting that future studies could extend 302 the RNA host viral classifier to identify specific viral pathogens, such as influenza or SARS-CoV-303 2, for which therapeutics exist. Future studies could additionally explore the use of targeted 304 enrichment methods^{28,29} to enhance detection of viral sepsis pathogen nucleic acid.

In line with prior reports¹³, we found that viral sepsis has a unique host transcriptional signature characterized by expression of interferon and other signaling pathways. We also observed transcriptional differences based on whether sepsis was due to a bloodstream versus peripheral site infection, which was less expected. The host response in Sepsis^{BSI} patients was characterized by lower expression of genes related to CD28 signaling and T cell activation, and greater expression of genes related to antimicrobial peptides, defensins and G alpha signaling, compared to Sepsis^{non-BSI} patients.

312 We found that detection of a pathogen alone was in many cases insufficient for sepsis 313 diagnosis, but when combined with a host transcriptional profile, had promising diagnostic utility

and potential as a tool for infection rule-out. In addition to defining host signatures of sepsis from whole blood, we also found biologically relevant host transcripts in plasma. This may have direct clinical applications given that plasma mNGS is increasingly being used in hospitals for pathogen detection in patients with sepsis and other infectious diseases, with turnaround times of \leq 48 hours.

319 Inappropriate antimicrobial use is a major challenge in the management of critical illness. 320 and is often driven by the inability to rule-out infection in patients with systemic inflammatory 321 diseases. Indeed, we found that clinical variables alone, including the gSOFA score, were 322 unable to accurately distinguish patients with sepsis from those with non-infectious critical 323 illnesses at the time of initial evaluation in the ED. In contrast, our proof-of-concept assessment 324 of the integrated host + microbe mNGS model demonstrated 99% sensitivity across patients 325 with microbiologically confirmed sepsis, and 78% specificity within the No-Sepsis group, which 326 was comprised almost entirely of patients meeting the clinical definition of systemic inflammatory response syndrome¹⁶. 327

Host/microbe mNGS may facilitate precision antimicrobial stewardship by discriminating sepsis from diverse types of non-infectious febrile inflammatory syndromes, ranging from autoimmune diseases to macrophage activation syndrome. We envision this assay being used at the time of ED presentation for all suspected sepsis patients, as an adjunct to blood cultures and other traditional microbiological testing.

Distinguishing true sepsis pathogens from environmental contaminants or human commensals (e.g., Gemella), is a challenge for both mNGS and traditional culture-based microbiologic methods. Concomitant assessment of a host-based metric offers an opportunity to determine whether the detected pathogen exists in the context of an immunological state consistent with infection. Considering this, host/microbe mNGS diagnostic classification could theoretically be more difficult in immunocompromised patients. Arguing against this, however, is prior work demonstrating accurate performance of a host/microbe mNGS pneumonia diagnostic

in an ICU cohort with a 40% prevalence of immunocompromised individuals¹⁴.

341 Our study has several strengths, including the novel use of plasma RNA transcriptomics 342 for sepsis diagnosis, development of the first sepsis diagnostic combining host and microbial 343 mNGS data, detailed clinical phenotyping, and a large prospective cohort of critically ill adults 344 with systemic illnesses. It also has some limitations. First, as noted above, mNGS and blood 345 cultures were performed on different samples collected at different times, so the observed 346 concordance with clinical microbiological testing may be an underestimate. Second, a significant 347 fraction of plasma samples had insufficient host transcripts to permit gene expression analyses, 348 leading to a smaller sample size for the plasma versus the whole blood cohorts. This limitation 349 may be addressable in future studies by increasing the input plasma volume and thus RNA 350 mass.

The host immune response during sepsis is dynamic, and thus the stage of infection at which gene expression is measured may influence accuracy of the classifier. While our study was cross-sectional in design, we attempted to control for this by sampling at a consistently early stage of critical illness, within the first 24 hours of ICU admission. Lastly, because we did not have access to any other sepsis studies with either plasma gene expression data or paired host and microbial mNGS data from blood, additional studies in an independent cohort will be needed to validate these findings.

In conclusion, we report that combining host gene expression profiling and metagenomic pathogen detection from plasma nucleic acid enables accurate diagnosis of sepsis. Future studies are needed to validate and test the clinical impact of this culture-independent diagnostic approach.



362

363 Figure 1, a) Study flow diagram. Patients studied were enrolled in the Early Assessment of Renal 364 and Lung Injury (EARLI) cohort. Sepsis adjudication performed following hospital discharge was 365 based on ≥ 2 or systemic inflammatory response syndrome (SIRS) criteria plus clinical suspicion 366 of infection, and was used to delineate 5 patient subgroups. Following guality control (QC), whole 367 blood underwent RNA-seg and plasma underwent RNA-seg and DNA-seg. b) Analytic 368 approaches. Host transcriptional sepsis diagnostic classifiers were trained and tested on RNA-369 seq data from whole blood (n=221) and plasma (n=110), with a goal of differentiating patients with microbiologically confirmed sepsis (Sepsis^{BSI} + Sepsis^{non-BSI}) from those without clinical evidence 370 371 of infection (No-Sepsis). Viral infections were identified via a secondary host transcriptomic 372 classifier. Sepsis pathogens were detected from plasma nucleic acid using metagenomic next 373 generation sequencing (mNGS) followed by a rules-based bioinformatics model (RBM). Finally, 374 an integrated host + microbe model for sepsis diagnosis was developed and evaluated.



376 Figure 2. Host gene expression differentiates patients with sepsis from those with non-infectious 377 critical illnesses. a) Heatmap of top 50 differentially expressed genes from whole blood 378 transcriptomics comparing patients with microbiologically confirmed sepsis (Sepsis^{BSI} + Sepsis^{non-} 379 ^{BSI}) versus those without evidence of infection (No-Sepsis). b) Gene set enrichment analysis of 380 the differentially expressed genes with the top 10 up- and down-regulated pathways (P < 0.05) 381 highlighted. c) Receiver operating characteristic (ROC) curve demonstrating performance of 382 bagged support vector machine (bSVM) classifier for sepsis diagnosis from whole blood 383 transcriptomics (n=221). The area under the ROC curve (AUC) and standard deviation (SD, in 384 parentheses, when applicable) are listed in the figure panel for cross validation (CV) in the training 385 set (red line: average over 10 random splits; red shaded area: ±1SD), the held-out validation set 386 (dashed grey line), and over 10 randomly-generated validation sets (solid grey line: average; grey 387 shaded area: ±1SD). d) Plasma RNA-seq expression differences of selected differentially 388 expressed genes previously identified as sepsis biomarkers, with Sepsis patients in maroon, and 389 No-Sepsis patients in grey. Adjusted P value provided above boxplot. Boxes represent the 25-75 390 percentiles and whiskers represent the 5-95 percentiles. e) ROC curve demonstrating 391 performance of bSVM classifier for sepsis diagnosis from plasma RNA (n=110). The AUC and 392 SD are listed in the figure panel for CV in the training set (red line: average over 10 random splits; 393 red shaded area: average ±1SD), the held-out validation set (dashed grey line), and over 10 394 randomly-generated validation sets (solid grey line: average; grey shaded area: average ±1SD).



396 Figure 3. Plasma metagenomic next generation sequencing (mNGS) for detecting sepsis 397 pathogens. a) Microbial plasma DNA mass differences between sepsis groups. Black bars 398 represent median and error bars represent the interguartile range. b) Graphical depiction of the 399 rules-based model (RBM) for sepsis pathogen detection from two different exemplary cases. The 400 RBM identifies established pathogens with disproportionately high abundance compared to other 401 commensal and environmental microbes in the sample. c) Concordance between plasma DNA mNGS for detecting bacterial pathogens in Sepsis^{BSI} patients with bacterial bloodstream 402 403 infections compared to a gold standard of culture. d) Sensitivity of plasma nucleic acid mNGS for detecting pathogens in Sepsis^{non-BSI} patients with sepsis from non-bloodstream, peripheral sites 404 405 of infection. Legend: LRTI = lower respiratory tract infection; UTI = urinary tract infection; CDI = 406 Clostridium difficile infection. Mass data are tabulated in Supplementary Data 8. Clinical 407 microbiology and metagenomics data are tabulated in Supplementary Data 9. *** = $P \le 0.001$. ** 408 $= P \le 0.01, * = P \le 0.05.$



410 Figure 4. Detection of viral sepsis based on host gene expression. a) GSEA of differentially 411 expressed genes from whole blood RNA-seg (n=129) demonstrating pathways enriched in 412 patients with viral sepsis. Gene sets with P < 0.05 included. b) GSEA of differentially expressed 413 genes from plasma RNA-seg (n=73) demonstrating pathways enriched in patients with viral 414 sepsis. Gene sets with P < 0.05 included. c) ROC curve demonstrating performance of bagged 415 support vector machine (bSVM) classifier for detecting viral sepsis from whole blood RNA-seq 416 (n=129). The area under the ROC curve (AUC) and standard deviation (SD, in parentheses, when 417 applicable) are listed in the figure panel for cross validation (CV) in the training set (red line: 418 average over 10 random splits; red shaded area: ±1SD), the held-out validation set (dashed grey 419 line), and over 10 randomly generated validation sets (solid grey line: average; grey shaded area: 420 ±1SD). d) ROC curve demonstrating performance of bSVM classifier for detecting viral sepsis 421 from plasma RNA-seq (n=73). The AUC and SD are listed in the figure panel for CV in the training 422 set (red line: average over 10 random splits; red shaded area: ±1SD), the held-out validation set 423 (dashed grey line), and over 10 randomly generated validation sets (solid grey line: average; grey 424 shaded area: ±1SD).



- 426 Figure 5. Integrated host-microbe mNGS model for sepsis diagnosis from plasma. Host criteria
- 427 for positivity can be met by a sepsis transcriptomic classifier probability > 0.5 (maroon bars,
- 428 dotted line). Microbial criteria can be met based on either: 1) detection of a pathogen by mNGS
- 429 and a sample microbial mass > 20 pg (grey bars), or 2) viral transcriptomic classifier probability
- 430 > 0.9 (blue circles, dotted line). Host and microbial metrics are highlighted for patients with
- 431 sepsis due to **a**) bloodstream infections (Sepsis^{BSI}), **b**) peripheral infection (Sepsis^{non-BSI}), **c**)
- 432 patients with non-infectious critical illness (No-Sepsis), and **d)** patients with suspected sepsis
- 433 but negative microbiological testing (Sepsis^{suspected}) and patients with indeterminant sepsis
- 434 status (Indeterm). Maroon cross: sepsis positive based on model. Blue circles: virus predicted
- 435 from plasma RNA secondary viral host classifier. Filled blue circles = virus also detected by
- 436 clinical respiratory viral PCR. Cases with < 20pg microbial mass indicated by lighter grey
- 437 shading. Samples with mNGS-detected pathogens have the microbe(s) listed below the sample
- 438 microbial mass. Raw values for plots and original training/test split assignments are tabulated in
- 439 Supplementary Data 16.

440 Methods

441 <u>Study design, clinical cohort, and ethics statement</u>

442 We conducted a prospective observational study of patients with acute critical illnesses 443 admitted from the ED to the ICU. We studied patients who were enrolled in the Early 444 Assessment of Renal and Lung Injury (EARLI) cohort at the University of California, San 445 Francisco (UCSF) or Zuckerberg San Francisco General Hospital between 10/2010 and 446 01/2018 (Supplementary Table 1). The study was approved by the UCSF Institutional Review 447 Board (IRB) under protocol 10-02852, which granted a waiver of initial consent for blood 448 sampling. Informed consent was subsequently obtained from patients or their surrogates for continued study participation, as previously described^{30,31}. 449 450 For the parent EARLI cohort, the inclusion criteria are: 1) age \geq 18, 2) admission to the 451 ICU from the ED, and 3) enrollment in the ED or within the first 24 hours of ICU admission. For 452 this study, we selected patients for whom PAXgene whole blood tubes and matched plasma 453 samples from the time of enrollment were available. PAXgene tubes were collected on patients 454 enrolled in EARLI during the time period listed above who were hypotensive and/or 455 mechanically ventilated at the time of enrollment. The main exclusion criteria for the EARLI 456 study are: 1) exclusively neurological, neurosurgical, or trauma surgery admission, 2) goals of 457 care decision for exclusively comfort measures, 3) known pregnancy, 4) legal status of prisoner, 458 and 5) anticipated ICU length of stay < 24 hours. Enrollment in EARLI began in 10/2008 and 459 continues.

460 Sepsis adjudication

461 Clinical adjudication of sepsis groups was carried out by study team physicians (MA, CL, 462 AL, KL, PS, CH, AG, CC, KK, MM) using the sepsis-2 definition³² (\geq 2 SIRS criteria + suspected 463 infection) and incorporating all available clinical and microbiologic data from the entire ICU 464 admission, with blinding to mNGS results. Each patient was reviewed by at least four

465 physicians. Disagreements were handled by discussion with the most senior physicians (CC, 466 MM) in the phenotyping panel. Patients were categorized into five subgroups based on sepsis 467 status (Figure 1a, Supplementary Figure 1). Patients with clinically adjudicated sepsis and a 468 bacterial culture-confirmed bloodstream infection (Sepsis^{BSI}), sepsis due to a microbiologically 469 confirmed primary infection at a peripheral site other than the bloodstream (Sepsis^{non-BSI}), 470 suspected sepsis with negative clinical microbiologic testing (Sepsis^{suspected}), patients with no 471 evidence of sepsis and a clear alternative explanation for their critical illness (No-Sepsis), or 472 patients of indeterminant status (Indeterm). Clinical and demographic features of patients are 473 summarized in (Supplementary Table 1) and tabulated in (Supplementary Data 16 and 17). 474 Metagenomic sequencing

475 Following enrollment, whole blood and plasma were collected in PAXgene and EDTA 476 tubes, respectively. Whole blood PAXgene tubes were processed and stored at -80C according 477 to manufacturer's instructions, and plasma was frozen at -80C within two hours. To evaluate 478 host gene expression and detect microbes, RNA-seq was performed on the whole blood and 479 plasma specimens, and DNA-seq was performed on plasma specimens. RNA was extracted 480 from whole blood using the Qiagen RNeasy kit and normalized to 10ng total input per sample. 481 Total plasma nucleic acid was extracted by first clarifying 300uL of plasma via maximum-speed 482 centrifugation for five minutes at 21,300 x g, and then employing the Zymo Pathogen Magbead 483 Kit on the supernatant following manufacturer's instructions. 10ng of total nucleic acid 484 underwent DNA-seq using the NEBNext Ultra II DNA Kit. Samples with at least 10ng of 485 remaining total nucleic acid were treated with DNAse (Qiagen) to recover RNA, and then 486 underwent RNA-seq library preparation using the NEBNext Ultra II RNA-seq Kit as described 487 below.

488 For RNA-seq library preparation, human cytosolic and mitochondrial ribosomal RNA and 489 globin RNA was first depleted using FastSelect (Qiagen). For the purposes of background

490 contamination correction (see below) and to enable estimation of input microbial mass, we 491 included negative water controls as well as positive controls (spike-in RNA standards from the External RNA Controls Consortium (ERCC))³³. RNA was then fragmented and underwent library 492 493 preparation using the NEBNext Ultra II RNA-seg Kit (New England Biolabs) according to 494 described methods. Finished libraries underwent 146 nucleotide paired-end Illumina 495 sequencing on an Illumina Novaseg 6000 instrument. 496 Index swapping can lead to read misassignment with Illumina sequencing. Dual 497 indexing, that is adding barcode index sequences on both ends of the molecule, reduces the 498 rate at which this misassignment occurs by requiring concordance between the two barcode 499 sequences. The frequency of index-swapped reads has been estimated to be more than 35X 500 lower when using dual vs single indexing³⁵. Because we used dual indexing and because the 501 RBM for pathogen detection operates by only identifying pathogen sequences 502 disproportionately abundant in a sample versus the other sequences, our methods would not be 503 expected to be negatively influenced by index swapping, which would only be anticipated to 504 misassign low abundance reads irrelevant to the RBM.

505 Host differential expression and pathway analysis

506 Following demultiplexing, sequencing reads were aligned with STAR³⁶ to an index 507 consisting of all transcripts associated with human protein coding genes (ENSEMBL v. 99), 508 cytosolic and mitochondrial ribosomal RNA sequences, and the sequences of ERCC RNA 509 standards. Samples retained in the dataset had a total of at least 50,000 counts associated with 510 transcripts of protein coding genes.

511 Differential expression analysis was performed using DESeq2 and including covariates 512 for age and gender. Significant genes were identified using an independent-hypothesis-513 weighted, Benjamini-Hochberg false discovery rate (FDR) < $0.1^{38,39}$. We generated heatmaps of 514 the top 50 differentially expressed genes by absolute log₂-fold change. To evaluate signaling

pathways from gene expression data, we employed gene set enrichment analysis using
WebGestalt⁴⁰ on all ranked differentially expressed genes with a P value < 0.1. Significant
pathways and upstream regulators were defined as those with a gene set P value < 0.05.

518 Pathogen detection

519 Detection of microbes leveraged the open-source IDseg pipeline²² which incorporates 520 subtractive alignment of the human genome (NCBI GRC h38) using STAR³⁶, guality and 521 complexity filtering, and subsequent removal of cloning vectors and phiX phage using 522 Bowtie2²². The identities of the remaining microbial reads are determined by guerying the NCBI 523 nucleotide (NT) database using GSNAP-L^{22,41}. After background correction (see below), 524 retained non-viral taxonomic alignments in each sample were aggregated at the genus level. 525 and sorted in descending order by abundance measured in reads per million (rpM), independently for each sample. A previously validated rules based model (RBM)¹⁴ was then 526 527 utilized to identify disproportionately abundant bacteria and fungi in each sample, and flag them 528 as pathogens. The RBM, originally developed to identify pathogens from respiratory mNGS 529 data, detects outlier organisms within a sample by identifying the greatest gap in abundance 530 between the top 15 sequentially ranked microbes in each sample. All microbes present in a 531 reference index of established pathogens above this gap are then called by the RBM.

532 We adapted the original RBM specifically for sepsis pathogen detection, in which outlier 533 organisms are sometimes present in low abundance, by incorporating a sepsis (as opposed to 534 respiratory) pathogen reference index (Supplementary Data 18) and requiring that the species 535 called by the RBM both be present in the reference index and detected at an abundance of > 1 536 rpM. Given the potential for respiratory viruses to cause sepsis, the RBM also identified human 537 pathogenic respiratory viruses derived from a reference list of LRTI pathogens¹⁴, present in the 538 plasma RNA-seq data at an abundance of > 1 rpM. Sensitivity and specificity were calculated 539 based on detection of reference index sepsis pathogens in each of the sepsis adjudication

540 groups.

541 The reference index (Supplementary Data 18) was established a. priori and no data 542 from the enrolled patients were used to inform the distinction between pathogens and 543 commensals. The index consisted of the most prevalent bloodstream infection pathogens reported by both the National Healthcare Safety Network (NHSN)⁴² and a recent multicenter 544 surveillance study of healthcare-associated infections⁴³. These studies reported multiple species 545 546 of Bacteriodes, Candida, Citrobacter, Enterobacter, Enterococcus, Klebsiella, Lactobacillus, 547 Morganella, Prevotella, Proteus, Serratia, Stenotrophomonas and Streptococcus as common 548 sepsis pathogens, and thus the reference index contains all species within these genera, 549 vielding > 1000 total species detectable by the model based on current NCBI taxonomy. 550 Identification and mitigation of environmental contaminants 551 Negative control samples consisting of only double-distilled water (n=24) were 552 processed alongside plasma DNA samples, which were sequenced in a single batch. Negative 553 control samples enabled estimation of the number of background reads expected for each 554 taxon⁴⁴. A previously developed negative binomial model⁴⁴ was employed to identify taxa with 555 NT sequencing alignments present at an abundance significantly greater compared to negative 556 water controls. This was done by modeling the number of background reads as a negative 557 binomial distribution, with mean and dispersion fitted on the negative controls. For each taxon, 558 we estimated the mean parameter of the negative binomial by averaging the read counts across 559 all negative controls. We estimated a single dispersion parameter across all taxa, using the 560 functions glm.nb() and theta.md() from the R package MASS⁴⁵. Taxa that achieved an adjusted 561 P value <0.01 (Benjamini & Hochberg multiple test correction) were carried forward to the 562 above-described RBM for pathogen detection.

563 Microbial mass calculations

Microbial mass was calculated based on the ratio of microbial reads in each sample to total reads aligning to the External RNA Controls Consortium (ERCC) RNA standards spiked into each sample⁴⁶. The following equation was utilized for this calculation: [ERCC input mass]/[microbial input mass] = [ERCC reads]/[microbial reads], where the ERCC input mass was 25pg.

569 Host transcriptional classifiers for sepsis and viral infection diagnosis

To build classifiers that differentiated patients with sepsis (Sepsis^{BSI}, Sepsis^{non-BSI}) from 570 571 those with non-infectious critical illness (No-Sepsis), and distinguished viral from non-viral sepsis, we built a Support Vector Machine (SVM)-based classifier⁴⁷ with the scikit-learn⁴⁸ 572 573 (v0.23.2) library in Python (v3.8.3). We tested several machine learning approaches (bagged 574 SVM, random forest and gradient boosted trees) and selected a bSVM classifier with a linear 575 kernel based on best performance (Supplementary Table 2). Each classifier used a 576 bootstrapped set of samples and a random subset of features. 577 We evaluated samples with \geq 50,000 plasma gene counts and genes with more than 578 20% non-zero counts in that sample subset. Only differentially expressed genes, identified using 579 DESeg2 (v1.28.1) in the training set, were considered as potential predictors and included in 580 machine learning models, with FDR thresholds of 0.1 (whole blood), 0.2 (plasma, viral) and 0.3 581 (plasma, sepsis) chosen based on cross-validation. Age and sex were included as covariates in 582 the models. We used Z-score-scaled transformed (variance stabilizing transformation) gene 583 counts. 75% of the data was selected to train the model, and the rest was used as a held-out 584 set to test the final model. The training set was subsequently randomly split ten times for cross-585 validation, using 75% of each as intermediate training sets, and the remaining 25% as their 586 associated testing sets.

587 On each one of those intermediate training sets, we carried out feature selection and 588 parameters optimization using nested 5-fold cross-validations. We optimized three parameters: 589 the regularization parameter, the maximum number of features considered for each classifier, 590 and the total number of classifiers to use for bagging. For each parameters optimization fold, a 591 recursive feature elimination (RFE) strategy was adopted, dropping 10% of the remaining least 592 important features at each iteration. A bSVM classifier with default parameters was built at each 593 iteration. We defined feature importance as the average squared weight across all estimators. 594 To maximize interpretability, we restricted the maximum number of predictors to 100 genes. 595 We estimated model performances using the Area Under the Receiver Operating 596 Characteristic Curve (AUC) values. To obtain a single set of features, we fitted a model, using 597 the aforementioned strategy, to the initial training set. This model was then tested on the held-598 out set to obtain a final performance value and a single set of predictors. 599 Comparison of plasma nucleic acid mNGS against clinician-ordered diagnostic testing 600 Clinical microbiological testing was carried out based on decisions from the primary 601 medical team during the patient's hospital admission at the UCSF and ZSFG clinical 602 microbiology laboratories Tests utilized included bacterial culture from blood, lower respiratory 603 tract and urine which were carried out according to previously described protocols¹⁴. Clinical 604 testing for viral respiratory pathogens was performed from nasopharyngeal swabs and/or 605 bronchioalveolar lavage using the Luminex XTag multiplex viral PCR assay. Polymicrobial blood 606 cultures with \geq 3 bacteria (n=2) were excluded from pathogen concordance given their unclear 607 clinical significance and potential that some organisms reflected contamination.

608 Integrated host + microbe sepsis diagnosis and rule-out model

609 We developed a simple integrated host + microbe model that returned a sepsis diagnosis based

- 610 on either host criteria [host sepsis classifier probability > 0.5] or microbial criteria:
- 611 [(pathogen detected by RBM) AND (microbial mass > 20 pg)] OR [host viral classifier

- 612 probability > 0.9]. Combined metrics (**Supplementary Data 16**) including sepsis assignment
- based on this model are depicted in Figure 5. Sensitivity was calculated in the (Sepsis^{BSI}) and

614 (Sepsis^{non-BSI}) groups, and specificity in the (No-Sepsis) group.

615

616 <u>Clinical variable models for sepsis diagnosis</u>

617 We tested the ability of clinical variables (Supplementary Table 3a) available at the 618 time of initial patient assessment to predict sepsis using three machine learning methods. These 619 included SVM using the e1071 package⁴⁹, random forest using the randomForest package⁵⁰ and regularized logistic regression using the glmnet⁵¹ package in R version 4.2.0⁵². Specifically, 620 we built models to classify Sepsis (Sepsis^{BSI} and Sepsis^{non-BSI}) versus No-Sepsis using 34 621 622 clinical variables that would be available at the time of ED evaluation. The data were split into 623 training (75%) and test (25%) sets and model performance (AUC) was evaluated on the test set. 624 This was repeated for a total of 10 randomized splits with the AUC computed at each iteration. 625 AUC was also computed for the qSOFA score (systolic blood pressure < 100 mmHg, respiratory 626 rate > 22 breaths/minute, Glasgow Coma Scale < 13). Results are tabulated in (Supplementary 627 Table 3b).

628 Statistics and reproducibility

629 Statistical tests utilized for each analysis are described in the figure legends and in 630 further detail in each respective methods section. The number of patient samples analyzed for 631 each comparison are indicated in the figure legends. Data were generated from single 632 sequencing runs without technical replicates.

633 Data availability

Source data are provided with this paper. The processed genecount data are available
 from the National Center for Biotechnology Information Gene Expression Omnibus database
 under accession code GSE189403. The raw sequencing data are protected due to data privacy

637	restri	ctions from the IRB protocol governing patient enrollment, which protects the release of
638	raw g	genetic sequencing data from those patients enrolled under a waiver of consent. To honor
639	this,	researchers who wish to obtain raw fastq files for the purposes of independently generating
640	gene	counts can contact the corresponding author (chaz.langelier@ucsf.edu) and request to be
641	adde	d to the IRB protocol. The raw fastq files with microbial sequencing reads are available
642	from	the Sequence Read Archive under BioProject ID: PRJNA783060.
643		
644	<u>Code</u>	e availability
645	Code	e for the differential expression, classifier development and RBM can be found at:
646	(http:	s://github.com/lucile-n/plasma_classifiers).
647		
648	Refe	rences
649	1. F	Rudd, K. E. <i>et al.</i> Global, regional, and national sepsis incidence and mortality, 1990–2017:
650	а	nalysis for the Global Burden of Disease Study. The Lancet 395 , 200–211 (2020).
651	2. L	iu, V. et al. Hospital Deaths in Patients With Sepsis From 2 Independent Cohorts. JAMA
652	3	12 , 90 (2014).
653	3. F	Paul, M. et al. Systematic Review and Meta-Analysis of the Efficacy of Appropriate Empiric
654	A	Antibiotic Therapy for Sepsis. Antimicrob Agents Chemother 54, 4851–4863 (2010).
655	4. F	Ferrer, R. et al. Empiric Antibiotic Treatment Reduces Mortality in Severe Sepsis and Septic
656	S	Shock From the First Hour: Results From a Guideline-Based Performance Improvement
657	F	Program*. Critical Care Medicine 42 , 1749–1755 (2014).
658	5. N	lovosad, S. A. et al. Vital Signs: Epidemiology of Sepsis: Prevalence of Health Care
659	F	actors and Opportunities for Prevention. MMWR Morb. Mortal. Wkly. Rep. 65, 864–869
660	(2	2016).

- 661 6. Lamy, B., Roy, P., Carret, G., Flandrois, J. & Delignette-Muller, M. L. What Is the Relevance
- of Obtaining Multiple Blood Samples for Culture? A Comprehensive Model to Optimize the
- 663 Strategy for Diagnosing Bacteremia. *CLIN INFECT DIS* **35**, 842–850 (2002).
- 664 7. Baur, D. *et al.* Effect of antibiotic stewardship on the incidence of infection and colonisation
- with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and
- 666 meta-analysis. *The Lancet Infectious Diseases* doi:10.1016/S1473-3099(17)30325-0.
- 8. Wilson, M. R. *et al.* Clinical Metagenomic Sequencing for Diagnosis of Meningitis and
 Encephalitis. *N. Engl. J. Med.* **380**, 2327–2340 (2019).
- 9. Blauwkamp, T. A. *et al.* Analytical and clinical validation of a microbial cell-free DNA
- 670 sequencing test for infectious disease. *Nature Microbiology* **4**, 663–674 (2019).
- 10. Lee, R. A., Al Dhaheri, F., Pollock, N. R. & Sharma, T. S. Assessment of the Clinical Utility
- of Plasma Metagenomic Next-Generation Sequencing in a Pediatric Hospital Population. J
 Clin Microbiol 58, (2020).
- 11. Hogan, C. A. *et al.* Clinical Impact of Metagenomic Next-Generation Sequencing of Plasma
- 675 Cell-Free DNA for the Diagnosis of Infectious Diseases: A Multicenter Retrospective Cohort
- 676 Study. *Clinical Infectious Diseases* **72**, 239–245 (2021).
- 677 12. Sweeney, T. E. *et al.* A community approach to mortality prediction in sepsis via gene
 678 expression analysis. *Nat Commun* **9**, 694 (2018).
- 13. Tsalik, E. L. *et al.* Host gene expression classifiers diagnose acute respiratory illness
- 680 etiology. Science Translational Medicine **8**, 322ra11-322ra11 (2016).
- 681 14. Langelier, C. *et al.* Integrating host response and unbiased microbe detection for lower
- respiratory tract infection diagnosis in critically ill adults. *Proc Natl Acad Sci USA* 201809700
- 683 (2018) doi:10.1073/pnas.1809700115.
- 15. Singer, M. *et al.* The Third International Consensus Definitions for Sepsis and Septic Shock
- 685 (Sepsis-3). *JAMA* **315**, 801 (2016).

686	16. Kaukonen, KM., Bailey, M., Pilcher, D., Cooper, D. J. & Bellomo, R. Systemic inflammatory
687	response syndrome criteria in defining severe sepsis. N. Engl. J. Med. 372, 1629–1638
688	(2015).
689	17. Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for
690	interpreting genome-wide expression profiles. Proceedings of the National Academy of
691	Sciences 102 , 15545–15550 (2005).
692	18. Demaret, J. et al. Identification of CD177 as the most dysregulated parameter in a
693	microarray study of purified neutrophils from septic shock patients. Immunology Letters 178,
694	122–130 (2016).
695	19. Tang, B. M. et al. Neutrophils-related host factors associated with severe disease and
696	fatality in patients with influenza infection. Nat Commun 10, 3422 (2019).
697	20. Cajander, S. et al. Preliminary results in quantitation of HLA-DRA by real-time PCR: a
698	promising approach to identify immunosuppression in sepsis. Crit Care 17, R223 (2013).
699	21. Leijte, G. P. et al. Monocytic HLA-DR expression kinetics in septic shock patients with
700	different pathogens, sites of infection and adverse outcomes. Crit Care 24, 110 (2020).
701	22. Kalantar, K. L. et al. IDseq—An open source cloud-based pipeline and analysis service for
702	metagenomic pathogen detection and monitoring. Gigascience 9, (2020).
703	23. Hall, K. K. & Lyman, J. A. Updated Review of Blood Culture Contamination. Clin Microbiol
704	<i>Rev</i> 19 , 788–802 (2006).
705	24. Langelier, C. et al. Detection of Pneumonia Pathogens from Plasma Cell-Free DNA. Am. J.
706	Respir. Crit. Care Med. (2019) doi:10.1164/rccm.201904-0905LE.
707	25. Libby, D. B. & Bearman, G. Bacteremia due to Clostridium difficile—review of the literature.
708	International Journal of Infectious Diseases 13, e305–e309 (2009).
709	26. Frencken, J. F. et al. Associations Between Enteral Colonization With Gram-Negative
710	Bacteria and Intensive Care Unit-Acquired Infections and Colonization of the Respiratory

711 Tract. Clinical Infectious Diseases **66**, 497–503 (2018).

- 712 27. Mudd, P. A. *et al.* Distinct inflammatory profiles distinguish COVID-19 from influenza with
- 713 limited contributions from cytokine storm. *Sci. Adv.* **6**, eabe3024 (2020).
- 28. Deng, X. et al. Metagenomic sequencing with spiked primer enrichment for viral diagnostics
- and genomic surveillance. *Nature Microbiology* (2020) doi:10.1038/s41564-019-0637-9.
- 29. Quan, J. *et al.* FLASH: a next-generation CRISPR diagnostic for multiplexed detection of
- antimicrobial resistance sequences. *Nucleic Acids Res.* (2019) doi:10.1093/nar/gkz418.
- 30. Auriemma, C. L. *et al.* Acute respiratory distress syndrome-attributable mortality in critically
- 719 ill patients with sepsis. *Intensive Care Med* **46**, 1222–1231 (2020).
- 31. Agrawal, A. *et al.* Plasma angiopoietin-2 predicts the onset of acute lung injury in critically ill
- 721 patients. *Am J Respir Crit Care Med* **187**, 736–742 (2013).
- 32. Levy, M. M. *et al.* 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions
- 723 Conference. *Crit Care Med* **31**, 1250–1256 (2003).
- 33. Pine, P. S. *et al.* Evaluation of the External RNA Controls Consortium (ERCC) reference
- 725 material using a modified Latin square design. *BMC Biotechnology* **16**, 54 (2016).
- 726 34. Mick, E. et al. Upper airway gene expression reveals suppressed immune responses to
- 527 SARS-CoV-2 compared with other respiratory viruses. *Nature Communications* **11**, (2020).
- 35. Wilson, M. R. et al. Multiplexed Metagenomic Deep Sequencing To Analyze the
- Composition of High-Priority Pathogen Reagents. *mSystems* **1**, e00058-16 (2016).
- 730 36. Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15–21 (2013).
- 37. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for
 RNA-seq data with DESeq2. *Genome Biology* **15**, 550 (2014).
- 733 38. Ignatiadis, N., Klaus, B., Zaugg, J. B. & Huber, W. Data-driven hypothesis weighting
- increases detection power in genome-scale multiple testing. *Nature Methods* **13**, 577–580
- 735 (2016).

- 39. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and
- Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society: Series B*(Methodological) 57, 289–300 (1995).
- 40. Liao, Y., Wang, J., Jaehnig, E. J., Shi, Z. & Zhang, B. WebGestalt 2019: gene set analysis
- toolkit with revamped UIs and APIs. *Nucleic Acids Research* **47**, W199–W205 (2019).
- 41. Zhao, Y., Tang, H. & Ye, Y. RAPSearch2: a fast and memory-efficient protein similarity

search tool for next-generation sequencing data. *Bioinformatics* **28**, 125–126 (2012).

- 42. Weiner-Lastinger, L. M. *et al.* Antimicrobial-resistant pathogens associated with adult
- healthcare-associated infections: Summary of data reported to the National Healthcare
- 745 Safety Network, 2015–2017. *Infect. Control Hosp. Epidemiol.* **41**, 1–18 (2020).
- 43. Magill, S. S. *et al.* Changes in Prevalence of Health Care–Associated Infections in U.S.

747 Hospitals. *New England Journal of Medicine* **379**, 1732–1744 (2018).

- 44. Mick, E. *et al.* Upper airway gene expression reveals suppressed immune responses to
- SARS-CoV-2 compared with other respiratory viruses. *Nature Communications* **11**, 5854
 (2020).
- 45. Venables, W. N. & Ripley, B. D. *Modern Applied Statistics with S.* (Springer-Verlag, 2002).
 doi:10.1007/978-0-387-21706-2.
- 46. Pine, P. S. *et al.* Evaluation of the External RNA Controls Consortium (ERCC) reference
 material using a modified Latin square design. *BMC Biotechnol* 16, 54 (2016).
- 755 47. Cortes, C. & Vapnik, V. Support-Vector Networks. *Mach. Learn.* **20**, 273–297 (1995).
- 48. Pedregosa, F. *et al.* Scikit-learn: Machine Learning in Python. *Journal of Machine Learning Research* 12, 2825–2830 (2011).
- 49. Meyer, D. *et al.* Package 'e1071'. https://cran.r-project.org/web/packages/e1071/e1071.pdf
 (2022).
- 50. Liaw, A. & Wiener, M. Classification and Regression by randomForest. *R News* 2, 18–22
 (2002).

- 762 51. Friedman, J., Hastie, T. & Tibshirani, R. Regularization Paths for Generalized Linear Models
- via Coordinate Descent. *Journal of Statistical Software, Articles* **33**, 1–22 (2010).
- 52. R Core Team. R: A Language and Environment for Statistical Computing. (R Foundation for
- 765 Statistical Computing, 2020).

Supplementary Materials

Supplementary Table 1a. Summary of clinical and demographic features of patients evaluated in whole blood gene expression analyses (n=221). These include patients with microbiologically confirmed sepsis (Sepsis^{BSI} and Sepsis^{non-BSI}) and those with non-infectious critical illnesses (No-Sepsis). Source data are tabulated in (Supplementary Data 16).

Whole Blood		Sepsis ^{BSI} (n=60)	Sepsis ^{non-BSI} (n=69)	No-Sepsis (n=92)	Sepsis vs No-Sepsis P value*
Age (median, Q1-Q3/%)		63.5 (50.8-73.3)	68 (58-80)	65.5 (54-74.5)	0.51
Gender (median, %)	Male Female Transgender	41 (68.3%) 19 (31.7%) 0 (0%)	40 (58%) 28 (40.6%) 1 (1.4%)	53 (57.6%) 39 (42.4%) 0 (0%)	0.49
	Caucasian Asian African	20 (33.3%) 17 (28.3%)	29 (42%) 21 (30.4%)	37 (40.2%) 24 (26.1%)	
Race (n, %)	American Other Unknown	10 (16.7%) 12 (20%) 0 (0%) 1 (1.7%)	5 (7.2%) 3 (4.3%)	17 (18.5%) 14 (15.2%) 0 (0%)	0.63
Ethnicity (n, %)	Non-LatinX LatinX NA	9 (15%) 0 (0%)	<u>60 (67%)</u> <u>60 (87%)</u> <u>6 (8.7%)</u> <u>3 (4.3%)</u>	<u>79 (85.9%)</u> 12 (13%) 1 (1.1%)	0.76
Temp Max (median, Q1-Q3%)		38.1 (37.1-38.9)	37.6 (37-38.4)	37.3 (36.1-37.9)	< 0.001
WBC Max (median, Q1-Q3%)		15.5 (10.1-23.8)	13.9 (9.5-19.2)	13.15 (9.5-18.9)	0.24
APACHEIII (median, Q1-Q3%)		69 (53-85)	50 (46-66)	64 (50-78)	0.17
SIRS	4 3 2 1	39 (65%) 16 (26.7%) 5 (8.3%) 0 (0%)	26 (37.7%) 30 (43.5%) 12 (17.4%) 0 (0.0%)	27 (29.3%) 42 (45.7%) 22 (23.9%) 1 (1.1%)	0.01
Bacterial infection [‡]		60 (100.0%)	50 (72.5%)	0 (0.0%)	< 0.001
Viral +/- Bacterial infection [‡]		3 (5.0%)	21 (30.4%)	0 (0.0%)	< 0.001
28-day mortality (n, %)		23 (38.3%)	15 (21.7%)	32 (34.8%)	0.49
Intubated (n, %)		47 (78.3%)	59 (85.5%)	86 (93.5%)	0.02
Vasopressors (n, %)		54 (90%)	51 (73.9%)	59 (64.1%)	< 0.01
Immunocompromised [#] (n, %)		7 (11.7%)	6 (8.7%)	6 (6.5%)	0.49
Antibiotics⁺ (n, %)		59 (98.3%)	66 (95.7%)	73 (79.3%)	< 0.001

*Sepsis^{BSI} + Sepsis^{non-BSI} vs No-Sepsis P value calculated by Mann-Whitney (continuous) or chi-squared (categorical) [‡]Based on clinical microbiology testing

[#]Immunocompromise was defined as: history of solid organ transplantation, bone marrow transplantation, HIV/AIDS with CD4 < 200, leukemia or other hematologic malignancy, autoimmune inflammatory disease, or primary immunodeficiency.</p>
*Antibiotics administered on or before the first day of study enrollment.

Supplementary Table 1b. Summary of clinical and demographic features of patients with plasma RNA-seq data, evaluated in all analyses (n=138). All sepsis adjudication groups represented. Source data are tabulated in (Supplementary Data 17).

		Sepsis ^{BSI}	Sepsis ^{non-BSI}	No-Sepsis	P value*	Sepsis ^{suspected}	Indeterm	Quarall
Plasma		(n=42) Modian/n	(n=31) Modion/n	(n=37) Modion/n	Sepsis ^{BSI+non-BSI} v No-Sepsis	(n=19) Modion/n	(n=9) Modion/n	Overall P value [†]
Age		63 5 (51 25-	(0.1-0.0/70)	(021-020770)		(0(1-0(0)/0)	(0.1-0.0/70)	
(median, Q1-Q3/%)		72)	69 (58-78.5)	66 (55-79)	0.45	69 (55-80)	72 (63-80)	0.12
Condor	Male	28 (66.7%)	17 (54.8%)	21 (56.8%)		9 (47.4%)	3 (33.3%)	
(median %)	Female	14 (33.3%)	14 (45.2%)	16 (43.2%)	0.77	9 (47.4%)	6 (66.7%)	0.24
(median, 70)	Transgender	0 (0%)	0 (0%)	0 (0%)		1 (5.3%)	0 (0%)	
	Caucasian	13 (31%)	12 (38.7%)	14 (37.8%)		4 (21.1%)	7 (77.8%)	
	Asian	12 (28.6%)	10 (32.3%)	13 (35.1%)		9 (47.4%)	1 (11.1%)	
	African American	8 (19%)	6 (19.4%)	7 (18.9%)	0.96	3 (15.8%)	1 (11.1%)	
Race (n, %)	Other	8 (19%)	2 (6.5%)	3 (8.1%)	0.00	3 (15.8%)	0 (0%)	0.50
	Native American	1 (2.4%)	0 (0%)	0 (0%)		0 (0%)	0 (0%)	
	Unknown	0 (0%)	1 (3.2%)	0 (0%)		0 (0%)	0 (0%)	
	Non-LatinX	36 (85.7%)	28 (90.3%)	35 (94.6%)		16 (84.2%)	8 (88.9%)	
Ethnicity (n, %)	LatinX	6 (14.3%)	2 (6.5%)	2 (5.4%)	0.48	3 (15.8%)	1 (11.1%)	0.62
	NA	0 (0%)	1 (3.2%)	0 (0%)		0 (0%)	0 (0%)	
Temp Max		38.05	37.8	37.1	< 0.01	37	35.8	< 0.001
(median, Q1-Q3/%)		(37.1-38.9)	(37.1-38.5)	(36.1-38)	< 0.01	(36.6-38.2)	(34.9-37.2)	< 0.001
WBC Max		16.05	17.4	13	0.40	19.3	15.3	0.60
(median, Q1-Q3/%)		(6.5-26.6)	(11.2-22.8)	(9.9-20.6)	0.40	(12.8-26.1)	(9.7-19.7)	0.00
APACHEIII (median, Q1-Q3/%)		72.5 (52-85)	54 (46-69)	72 (57-81)	0.20	70 (61-89)	72 (65-93)	0.04
	4	28 (66.7%)	13 (41.9%)	15 (40.5%)		12 (63.2%)	5 (55.6%)	
SIRS	3	11 (26.2%)	15 (48.4%)	15 (40.5%)	0.10	5 (26.3%)	3 (33.3%)	0.52
6116	2	3 (7.1%)	3 (9.7%)	6 (16.2%)	0.15	2 (10.5%)	1 (11.1%)	
	1	0 (0%)	0 (0%)	1 (2.7%)		0 (0%)	0 (0%)	
Bacterial infection [‡]		42 (100.0%)	24 (77.4%)	0 (0.0%)	< 0.001	0 (0.0%)	0 (0.0%)	1.00
Viral +/- Bacterial infection [‡]		2 (4.8%)	11 (35.5%)	0 (0.0%)	< 0.001	0 (0.0%)	0 (0.0%)	1.00
28-day mortality (n, %)		20 (47.6%)	8 (25.8%)	18 (48.6%)	0.41	11 (57.9%)	7 (77.8%)	0.04
Intubated (n, %)		32 (76.2%)	28 (90.3%)	35 (94.6%)	0.13	18 (94.7%)	9 (100%)	0.05
Vasopressors (n, %)		40 (95.2%)	23 (74.2%)	31 (83.8%)	0.95	18 (94.7%)	8 (88.9%)	0.08
Immunocompromised [#] (n, %)		6 (14.3%)	5 (16.1%)	4 (10.8%)	0.75	5 (26.3%)	2 (22.2%)	0.63
Antibiotics⁺ (n, %)		41 (97.6%)	31 (100.0%)	31 (83.8%)	< 0.01	19 (100.0%)	8 (88.9%)	0.02

*Mann-Whitney (continuous) /chi-squared (categorical) †Kruskal-Wallis (continuous) / chi-squared (categorical)

[‡]Based on clinical microbiology testing

[#]Immunocompromise was defined as: history of solid organ transplantation, bone marrow transplantation, HIV/AIDS with CD4 < 200, leukemia or other hematologic malignancy, autoimmune inflammatory disease, or primary immunodeficiency.

⁺Antibiotics administered on or before the first day of study enrollment.

Supplementary Table 2. Comparison of machine learning models for host-based sepsis classification. Area under the receiver operator characteristic curve (AUC) for three different machine learning models assessed for classifier construction. The AUC for cross-validation in the training set (standard deviation in parentheses) is listed first, and the AUC for the first validation split is listed second, after the vertical bar. The bagged support vector machine (bSVM) model performed best overall.

Classifier	Bagged Support Vector Machine	Random Forest	Gradient Boosted Tree
Whole blood - sepsis	0.81 (0.05) 0.82	0.80 (0.06) 0.86	0.79 (0.05) 0.84
Plasma - sepsis	0.97 (0.03) 0.77	0.76 (0.05) 0.79	0.70 (0.09) 0.82
Whole blood - viral	0.90 (0.07) 0.79	0.83 (0.08) 0.75	0.78 (0.07) 0.69
Plasma - viral	0.94 (0.09) 0.96	0.77 (0.09) 0.81	0.72 (0.19) 0.60

Supplementary Table 3a. Clinical variables used for classifier construction. Fever: > 38C, anemia: hemoglobin < 7, thrombocytopenia: platelets < 50, acute renal failure: creatinine > 2.0.

Anemia	Temp Max	Creatinine Max
Hyperkalemia	Fever	Creatinine Min
Hypokalemia	Temp Min	Acute Renal Failure
Hypernatremia	WBC Max	Platelets Min
Hyponatremia	WBC Min	Thrombocytopenia
Hypercalcemia	HR Max	Requirement for Intubation
Hypocalcemia	HR Min	Glasgow Coma Scale
Hyperthyroid	RR Max	Immunocompromise
Hypothyroid	RR Min	Chest Pain
Adrenal Insufficiency	SIRS total	Volume Overload
Hyperglycemia	SBP Min	Creatinine Max
Hypoglycemia	SBP Max	Creatinine Min

Supplementary Table 3b. Average classifier AUC over 10 iterations of training and test from different machine learning classifiers to distinguish Sepsis from No-Sepsis patients using clinical features alone. qSOFA score positive for sepsis if systolic blood pressure < 100 mmHg, respiratory rate > 22 breaths/minute and Glasgow Coma Scale < 13.

Method	AUC, mean (std)
Support vector machine	0.57 (0.04)
Random forest	0.62 (0.04)
Regularized logistic regression	0.57 (0.07)
qSOFA score	0.48 (0.02)



Supplementary Figures

Supplementary Figure 1. Overlap of significant genes in the differential expression analyses between the Sepsis and No-Sepsis groups for whole blood and plasma samples. Scatter plot of -log10(adjusted p-value) for individual genes from the differential expression analyses comparing patients with microbiologically confirmed sepsis (Sepsis^{BSI} + Sepsis^{non-BSI}) versus those without evidence of infection (No-sepsis), from whole blood (x-axis) and plasma (y-axis). P-values derive from Benjamini-Hochberg adjustment. Dashed gray lines indicate the threshold of adjusted p-value < 0.1. Selected, significant, differentially expressed genes highlighted in blue.



Supplementary Figure 2. Plasma host gene expression differentiates patients with sepsis from those with non-infectious critical illnesses. a) Heatmap of top 50 differentially expressed genes from whole blood transcriptomics comparing patients with microbiologically confirmed sepsis (Sepsis^{BSI} + Sepsis^{non-BSI}) versus those without evidence of infection (No-sepsis).
b) Gene set enrichment analysis of the differentially expressed genes. All gene sets included.

Supplementary Data Files

- Supplementary Data 1. Differentially expressed genes (adjusted P value < 0.1) between patients with microbiologically confirmed (Sepsis^{BSI} and Sepsis^{non-BSI}) and those with non-infectious critical illnesses (No-Sepsis), from whole blood RNA-seq.
- Supplementary Data 2. Gene set enrichment analysis of differentially expressed genes between patients with microbiologically confirmed sepsis (Sepsis^{BSI} and Sepsis^{non-BSI}) and those with non-infectious critical illnesses (No-Sepsis). Data from whole blood RNA-seq. The top 10 positively and negatively enriched pathways by P value are included in table.
- Supplementary Data 3. Differentially expressed genes (adjusted P value < 0.1) between patients with sepsis due to bloodstream infections (Sepsis^{BSI}) versus peripheral infections (Sepsis^{non-BSI}). Data from whole blood RNA-seq.
- Supplementary Data 4. Gene set enrichment analysis of differentially expressed genes between patients with sepsis due to bloodstream infections (Sepsis^{BSI}) versus peripheral infections (Sepsis^{non-BSI}). Data from a) whole blood RNA-seq and b) plasma RNA-seq. The top 10 positively and negatively enriched pathways by P value are included in table.
- Supplementary Data 5. a) Area under the receiver operating characteristic curve (AUC) values for 10 independent training set models for a whole blood gene expression support vector machine classifier to distinguish patients with microbiologically confirmed (Sepsis^{BSI} and Sepsis^{non-BSI}) from those with non-infectious critical illnesses (No-Sepsis). b) Composite list of all genes selected by each classifier model.

- Supplementary Data 6. Differentially expressed genes (adjusted P value < 0.1) between patients with microbiologically confirmed (Sepsis^{BSI} and Sepsis^{non-BSI}) and those with non-infectious critical illnesses (No-Sepsis), from plasma RNA-seq.
- Supplementary Data 7. a) AUC values for 10 independent training set models for a plasma gene expression support vector machine classifier to distinguish patients with microbiologically confirmed (Sepsis^{BSI} and Sepsis^{non-BSI}) from those with non-infectious critical illnesses (No-Sepsis). b) Composite list of all genes selected by each classifier model.
- Supplementary Data 8. Mass (pg) of microbial DNA in each sample, calculated based on spiked-in 25 pg ERCC positive controls.

Supplementary Data 9. Sepsis pathogens detected by standard of care clinical microbiology versus plasma mNGS, using the rules-based model.

- Supplementary Data 10. Differentially expressed genes (adjusted P value < 0.1) between patients with microbiologically confirmed viral sepsis and those with non-viral sepsis (Sepsis^{BSI} and Sepsis^{non-BSI} groups), from whole blood RNA-seq.
- Supplementary Data 11. Differentially expressed genes (adjusted P value < 0.1) between patients with microbiologically confirmed viral sepsis and those with non-viral sepsis (Sepsis^{BSI} and Sepsis^{non-BSI} groups), from plasma RNA-seq.
- Supplementary Data 12. Gene set enrichment analysis of differentially expressed genes between patients with viral versus non-viral causes of sepsis amongst the Sepsis^{BSI} and Sepsis^{non-BSI} patients. a) Data from whole blood RNA-seq. b) Data from plasma RNA-seq.

Supplementary Data 13. a) AUC values for 10 independent training set models for a whole blood gene expression support vector machine classifier to distinguish patients with microbiologically confirmed viral versus non-viral sepsis (Sepsis^{BSI} and Sepsis^{non-BSI}), from whole blood RNA-seq. b) Composite list of all genes selected by each classifier model.

- Supplementary Data 14. a) AUC values for 10 independent training set models for a plasma gene expression support vector machine classifier to distinguish patients with microbiologically confirmed viral versus non-viral sepsis (Sepsis^{BSI} and Sepsis^{non-BSI}), from plasma RNA-seq. b) Composite list of all genes selected by each classifier model.
- Supplementary Data 15. Complete integrated host-microbe mNGS dataset. This includes: persample classifier predictions for all patients with plasma sequencing data (n=138), including the sepsis diagnostic classifier and the viral sepsis classifier; pathogens detected by clinical diagnostics and by mNGS; and microbial mass per sample.
- Supplementary Data 16. Clinical and demographic features of patients evaluated in whole blood gene expression analyses only (n=221). These include patients with microbiologically confirmed sepsis (Sepsis^{BSI} and Sepsis^{non-BSI}) and those with (No-Sepsis).
- Supplementary Data 17. Clinical and demographic features of patients with plasma RNA-seq data, evaluated in all analyses (n=138). All sepsis adjudication groups represented.
- Supplementary Data 18. Reference index of established sepsis pathogens derived from the top 20 most prevalent sepsis pathogens reported by both the US CDC/ National Healthcare Safety Network¹ and a point prevalence survey of healthcare-associated infections².

Supplementary References

- Weiner-Lastinger, L. M. *et al.* Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network, 2015–2017. *Infect. Control Hosp. Epidemiol.* 41, 1–18 (2020).
- Magill, S. S. *et al.* Changes in Prevalence of Health Care–Associated Infections in U.S. Hospitals. *New England Journal of Medicine* **379**, 1732–1744 (2018).